High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology
Abstract Progesterone (P4), commonly administered in high doses for endometrial cancer palliative management, has limitations in current delivery systems. This preliminary in vitro drug release study introduces electrospun patches to offer a new perspective on P4 delivery. The study aimed to assess...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2024-04-01
|
| Series: | Macromolecular Materials and Engineering |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mame.202300447 |
| _version_ | 1797207582823153664 |
|---|---|
| author | Omar Shafi Saurabh Phadnis Un Hou Chan Mohan Edirisinghe Francis Brako |
| author_facet | Omar Shafi Saurabh Phadnis Un Hou Chan Mohan Edirisinghe Francis Brako |
| author_sort | Omar Shafi |
| collection | DOAJ |
| description | Abstract Progesterone (P4), commonly administered in high doses for endometrial cancer palliative management, has limitations in current delivery systems. This preliminary in vitro drug release study introduces electrospun patches to offer a new perspective on P4 delivery. The study aimed to assess the influence of the surfactant polysorbate 80 (PS80) on the release of P4 from polycaprolactone (PCL) fibers. The PS80 effects are examined to inform the fine‐tuning of the fibre generation process. Patches developed, PCL wet (with PS80) and PCL dry (without PS80), showed encapsulation efficiencies of 76% and 42%, respectively. The dose levels studied are 6.1 mg for PCL wet and 4.4 mg for PCL dry samples. Molecular studies show that higher surfactant levels improved P4‐polymer mixing, enhancing dissolution and release rates. Patches with PS80 released 66% of the drug in 17 h, while those without released only 51%. Release data best fit the Weibull model, showcasing promise for these patches in transdermal P4 delivery. This study offers a non‐invasive option compared to traditional methods and underscores the need for further research to confirm the patches' clinical effectiveness for potential use in gynecological oncology. |
| first_indexed | 2024-04-24T09:25:12Z |
| format | Article |
| id | doaj.art-f39a027b6bb14cefabd5b0f061b8b446 |
| institution | Directory Open Access Journal |
| issn | 1438-7492 1439-2054 |
| language | English |
| last_indexed | 2024-04-24T09:25:12Z |
| publishDate | 2024-04-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | Macromolecular Materials and Engineering |
| spelling | doaj.art-f39a027b6bb14cefabd5b0f061b8b4462024-04-15T15:13:55ZengWiley-VCHMacromolecular Materials and Engineering1438-74921439-20542024-04-013094n/an/a10.1002/mame.202300447High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological OncologyOmar Shafi0Saurabh Phadnis1Un Hou Chan2Mohan Edirisinghe3Francis Brako4Torrington Place, Department of Mechanical Engineering University College London (UCL) London WC1E 6BT UKLondon Gynaecology 15 Austin Friars London EC2N 2HE UKTorrington Place, Department of Mechanical Engineering University College London (UCL) London WC1E 6BT UKTorrington Place, Department of Mechanical Engineering University College London (UCL) London WC1E 6BT UKFaculty of Engineering and Science, Department of ScienceUniversity of GreenwichChatham ME4 4TB UKAbstract Progesterone (P4), commonly administered in high doses for endometrial cancer palliative management, has limitations in current delivery systems. This preliminary in vitro drug release study introduces electrospun patches to offer a new perspective on P4 delivery. The study aimed to assess the influence of the surfactant polysorbate 80 (PS80) on the release of P4 from polycaprolactone (PCL) fibers. The PS80 effects are examined to inform the fine‐tuning of the fibre generation process. Patches developed, PCL wet (with PS80) and PCL dry (without PS80), showed encapsulation efficiencies of 76% and 42%, respectively. The dose levels studied are 6.1 mg for PCL wet and 4.4 mg for PCL dry samples. Molecular studies show that higher surfactant levels improved P4‐polymer mixing, enhancing dissolution and release rates. Patches with PS80 released 66% of the drug in 17 h, while those without released only 51%. Release data best fit the Weibull model, showcasing promise for these patches in transdermal P4 delivery. This study offers a non‐invasive option compared to traditional methods and underscores the need for further research to confirm the patches' clinical effectiveness for potential use in gynecological oncology.https://doi.org/10.1002/mame.202300447drug releaseelectrospinningfunctional biomaterialsgynecologyoncologypalliative care |
| spellingShingle | Omar Shafi Saurabh Phadnis Un Hou Chan Mohan Edirisinghe Francis Brako High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology Macromolecular Materials and Engineering drug release electrospinning functional biomaterials gynecology oncology palliative care |
| title | High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology |
| title_full | High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology |
| title_fullStr | High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology |
| title_full_unstemmed | High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology |
| title_short | High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology |
| title_sort | high dose progesterone loaded pcl polysorbate 80 transdermal fibers for potential application in gynecological oncology |
| topic | drug release electrospinning functional biomaterials gynecology oncology palliative care |
| url | https://doi.org/10.1002/mame.202300447 |
| work_keys_str_mv | AT omarshafi highdoseprogesteroneloadedpclpolysorbate80transdermalfibersforpotentialapplicationingynecologicaloncology AT saurabhphadnis highdoseprogesteroneloadedpclpolysorbate80transdermalfibersforpotentialapplicationingynecologicaloncology AT unhouchan highdoseprogesteroneloadedpclpolysorbate80transdermalfibersforpotentialapplicationingynecologicaloncology AT mohanedirisinghe highdoseprogesteroneloadedpclpolysorbate80transdermalfibersforpotentialapplicationingynecologicaloncology AT francisbrako highdoseprogesteroneloadedpclpolysorbate80transdermalfibersforpotentialapplicationingynecologicaloncology |